David Grainger Raises very nicely (but does not answer!) the question of orphan drug pricing. James Your comments caused me to do some math, and trying to figure out just where and how long the “break even” point lies with the drug.

Last night, NPS Pharmaceuticals announced that it was pricing Gattex, its drug for short bowel syndrome, at $295,000 per patient per year, Continue reading →